Fusion Pharmaceuticals Q4 2023 GAAP EPS $(0.39) Misses $(0.34) Estimate
Portfolio Pulse from Benzinga Newsdesk
Fusion Pharmaceuticals reported a Q4 2023 GAAP EPS of $(0.39), missing the consensus estimate of $(0.34) by 14.71%.
March 20, 2024 | 8:22 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Fusion Pharmaceuticals reported a Q4 2023 GAAP EPS of $(0.39), missing the consensus estimate of $(0.34) by 14.71%.
Missing the consensus estimate for earnings per share (EPS) typically leads to negative investor sentiment in the short term, potentially causing a decrease in stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100